The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Postdoctoral Researcher”
Reference: 2024-057-01
Application deadline: Until filled
Number of vacancies: 1
Job description:
The Cancer Genome Engineering Group has an open position for a postdoctoral researcher to join the team. We are looking for a motivated scientist capable of leading their research project and wanting to work as a team member in a collegial and supportive environment.
Our group is centered in understanding how copy number alterations (CNAs) contribute to disease progression and therapy resistance. We are particularly interested in the role of CNAs driving immune evasion, intra-tumor heterogeneity, and cancer genome evolution.
To answer this major challenge we use state of the art genome engineering approaches combined with in vivo models of cancer to gain deep mechanistic insight on the biology of CNAs.
The postdoctoral researcher will work on developing in vitro and in vivo mouse models of cancer, along with novel genome engineering methods to study the clinically relevant CNAs. The project also entails the incorporation of CRISPR-Cas9 screens (in vitro and in vivo), as well as the in-depth analysis of anti-tumor immunity during disease progression and in response to immunotherapy.
Development of in vitro and in vivo models:
• Design and conduct experiments using cancer models, including mouse models, to study copy number alterations (CNAs).
Application of genome engineering techniques:
• Utilize advanced genome-editing methods, such as CRISPR-Cas9, to investigate clinically relevant CNAs.
Execution of CRISPR-Cas9 screens:
• Implement and analyze CRISPR-Cas9 screens, both in vitro and in vivo, to identify genes involved in cancer progression and therapy resistance.
Study of anti-tumor immunity:
• Investigate the impact of CNAs on anti-tumor immune responses during cancer progression and in response to immunotherapy.
Collaboration and teamwork:
• Work closely with team members in a collaborative and supportive environment, contributing to collective research goals.
Data analysis and interpretation:
• Analyze experimental data and interpret findings to understand the mechanistic role of CNAs in cancer biology and therapy resistance.
Presentation and publication of research:
• Present research findings at conferences and contribute to scientific publications.
Requirements:
What do we need?
- PhD degree in biomedical research or similar field (degree not needed at the time of application but will be required when the successful candidate joins the group).
- Prior experience with cancer genetics and mouse models will be viewed positively but are not strict requirements.
What we offer?
- The possibility of developing your professional career in a competitive environment.
- To be part of a centre that is constantly developing, pursuing excellence in research and collaborating with leading teams.
- We offer and promote a diverse and inclusive environment, and welcome all people equally, regardless of age, disability, gender, nationality, race, religion or sexual orientation.
Working conditions:
- Full-time contract.
- Salary will be estimated according to profile and experience.
- Immediate incorporation.
- Flexible working hours and measures to reconcile work, family, personal life and gender equality, as stipulated in the VHIO agreement.
- Flexible remuneration programme (including restaurant vouchers, medical insurance, transport and childcare vouchers).
- 23 days of holiday and 5 days of free disposal.
- Access to VHIO's personal development and training plan.
Application:
Candidates must submit a curriculum vitae, a cover letter, and the contact information of two references addressed to selecciorrhh@vhio.net and fbarriga@vhio.net including the reference “Ref. 2024-057-01” in the subject line of their email. Applications will be reviewed immediately, and interviews will be arranged with short-listed candidates.
About VHIO:
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.